Search details
1.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Lancet Oncol
; 25(3): 308-316, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38423047
2.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38043558
3.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38621400
4.
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.
Radiology
; 311(1): e231703, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38563674
5.
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
J Urol
; : 101097JU0000000000004010, 2024 May 21.
Article
in English
| MEDLINE | ID: mdl-38758680
6.
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
BJU Int
; 133 Suppl 3: 39-47, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37604702
7.
Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Br J Haematol
; 201(3): 502-509, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37015002
8.
177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer.
Radiology
; 306(2): e220859, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36125377
9.
A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.
Radiology
; 307(4): e222010, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37070991
10.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37246997
11.
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
BJU Int
; 131(5): 588-595, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36371669
12.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36261050
13.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Article
in English
| MEDLINE | ID: mdl-33581798
14.
Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-AJR Expert Panel Narrative Review.
AJR Am J Roentgenol
; 218(5): 767-780, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34985313
15.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
; 22(8): 1115-1125, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34246328
16.
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Lancet
; 395(10231): 1208-1216, 2020 04 11.
Article
in English
| MEDLINE | ID: mdl-32209449
17.
Prostate-specific Membrane Antigen PET in Prostate Cancer.
Radiology
; 299(2): 248-260, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33787338
18.
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Eur J Nucl Med Mol Imaging
; 48(5): 1626-1638, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33604691
19.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34028967
20.
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).
BJU Int
; 128(3): 331-342, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33682320